Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Capecitabine in Advanced Gastric Cancer
NCT00142038Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2004
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel and capecitabine in gastric cancer (GC) (2 cohorts), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Response Rate. Started Mar 2004; status: completed.
02
Drugs
docetaxelcapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00142038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142038.